Ultrasound and Radiological Patterns in Assessing the Efficacy of Juvelook for Collagen Stimulation and Tear Trough Enhancement: A Case Report

Tear trough deformity, in the presence of hollows, shadows, and lax skin underneath the eyes, is a common cosmetic concern. Frequent application of non-surgical treatments, such as hyaluronic acid (HA) fillers and fat grafting, can result in complications, such as the Tyndall effect and vascular occlusion. Juvelook (VAIM Global Inc., Seoul, South Korea), a new hybrid filler HA/poly-D,L-lactic acid (PDLLA), exhibits immediate volumization through gain in skin thickness and secondary delayed collagen stimulation. A 24-year-old female with moderate hollowness, pigmentation, and laxity of the skin in the under-eye region required non-surgical rejuvenation. Clinical and radiological evaluations (ultrasonography, CT, MRI) were conducted. Bilateral Juvelook injection was performed using a supraperiosteal and subdermal cannula. On day 18 after the procedure, the patient demonstrated a better skin texture, reduced hollowness, and very high satisfaction. Imaging revealed excellent integration of the filler with no side effects. Juvelook can potentially serve as an effective and safe solution for tear trough rejuvenation. HA injects immediate volumization, whereas PDLLA stimulates collagen to ensure long-lasting correction. The cannula technique keeps complications at bay in such delicate areas. The absence of adverse effects and satisfactory results ensures biocompatibility and effectiveness. Large controlled trials, however, need to be performed to confirm these findings and compare them to existing treatments. This case report documents the efficacy of Juvelook in tear trough rejuvenation with immediate volumetric gain and skin texture enhancement. The cannula technique minimized risk, and imaging confirmed its biocompatibility. Therefore, additional studies are required to establish long-term safety, optimal injection techniques, and comparisons with other treatment modalities.